Insider Selling: Tempus AI (NASDAQ:TEM) CAO Sells $171,363.10 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 2,902 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $171,363.10. Following the sale, the chief accounting officer owned 41,159 shares of the company’s stock, valued at approximately $2,430,438.95. This represents a 6.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Tempus AI Stock Down 2.7%

NASDAQ TEM opened at $58.37 on Monday. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The stock has a market capitalization of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The business’s 50-day moving average is $62.35 and its 200 day moving average is $73.62.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada lifted its position in Tempus AI by 201.2% during the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after acquiring an additional 17,359 shares during the period. Rhumbline Advisers bought a new position in shares of Tempus AI during the first quarter valued at approximately $116,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Tempus AI during the second quarter valued at approximately $307,000. Atria Wealth Solutions Inc. purchased a new position in shares of Tempus AI during the second quarter valued at approximately $214,000. Finally, Allianz Asset Management GmbH boosted its position in shares of Tempus AI by 52.9% in the 2nd quarter. Allianz Asset Management GmbH now owns 10,400 shares of the company’s stock worth $661,000 after purchasing an additional 3,600 shares in the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. decreased their target price on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Morgan Stanley upped their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Mizuho started coverage on shares of Tempus AI in a research report on Thursday. They set an “outperform” rating and a $100.00 price target on the stock. Finally, Robert W. Baird started coverage on shares of Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tempus AI currently has an average rating of “Hold” and an average target price of $85.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.